Otsuka is acquiring Transcend Therapeutics to add an experimental neuropsychiatric asset aimed at restoring “neuroplasticity,” in a deal valued at roughly $1.2 billion, including a $700 million upfront payment and additional milestone consideration. Transcend’s lead compound TSND-201 is a methylone analog designed to rapidly and sustainably enhance neuroplasticity in psychiatric conditions such as post-traumatic stress disorder. The companies said they expect the transaction to close between April and the end of June, subject to customary closing conditions. Transcend also framed TSND-201 as avoiding a specific serotonin receptor targeted by MDMA-like compounds associated with hallucinogenic effects. Clinical development is already underway: results from a mid-stage PTSD study were published in JAMA Psychiatry, and recruitment for a U.S. Phase 3 trial is ongoing. The acquisition signals how major pharma is continuing to prioritize CNS mechanisms tied to synaptic rewiring rather than traditional symptomatic modulation. For the sector, it adds another large-company bet in a space where regulatory and stigma concerns have historically been barriers, but where evolving evidence standards and trial designs are enabling scale-up.